LTI-01

June 8, 2017June 8, 2017

Lung Therapeutics Announces $14.3 Million in Funding to Continue Research on Potential Disease Therapies

Lung Therapeutics, which specializes in therapies for fibrosis, lung injury and lung disease, announced that it has raised $14.3 million in Series B financing. The funding will support ongoing clinical trials in Australia ... Read more

November 3, 2015

NIH Grant to Advance Lung Therapeutics’ Empyema Drug Therapy

News, Pneumonia

The National Institutes of Health (NIH) will support research conducted by Dr. Steven Idell, MD, PhD, who serves as UT Health Northeast investigator and chief scientific officer of the pharmaceutical company ... Read more

January 14, 2015January 14, 2015

Lung Therapeutics’ Empyema Drug Receives European Orphan Medicinal Product Status

News, Pneumonia

Pharmaceutical company Lung Therapeutics, Inc. has received the orphan medicinal product designation from the European Commission (EC) for its lead drug candidate LTI-01 for the treatment of empyema, a complication related to pneumonia. The status was ... Read more

December 3, 2014November 11, 2015

Lung Therapeutics Empyema Treatment Receives Orphan Drug Designation

COPD, News

Austin-based Lung Therapeutics, Inc., a pharmaceutical company developing treatments for niche lung diseases, has just announced that the US Food and Drug Administration has granted an Orphan Drug Designation for LTI-01, an ... Read more

October 29, 2014November 5, 2015

Fresh Funding For Lung Injury, IPF Drug Candidate

Idiopathic Pulmonary Fibrosis, News

Pharmaceutical company Lung Therapeutics recently announced an initial closing of $1,550,000 on its Series A Preferred Stock financing, which is comprised of $550,000 in converted debt, as well as a remaining funding of $1,200,000 ... Read more